The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 04, 2020
Filed:
Jun. 16, 2015
Applicant:
University of Rochester, Rochester, NY (US);
Inventors:
Richard P. Phipps, Pittsford, NY (US);
Collynn Woeller, Webster, NY (US);
Assignee:
University of Rochester, Rochester, NY (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/7048 (2006.01); A61K 45/06 (2006.01); A61K 31/167 (2006.01); A61K 31/351 (2006.01); A61K 31/166 (2006.01); A61K 31/341 (2006.01); A61K 31/381 (2006.01); A61K 31/415 (2006.01); A61K 31/4184 (2006.01); A61K 31/4409 (2006.01); A61K 31/4412 (2006.01); A61K 31/47 (2006.01); A61K 31/519 (2006.01); A61K 31/5375 (2006.01); A61K 31/549 (2006.01); A61K 31/551 (2006.01); A61K 31/635 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7048 (2013.01); A61K 31/166 (2013.01); A61K 31/167 (2013.01); A61K 31/341 (2013.01); A61K 31/351 (2013.01); A61K 31/381 (2013.01); A61K 31/415 (2013.01); A61K 31/4184 (2013.01); A61K 31/4409 (2013.01); A61K 31/4412 (2013.01); A61K 31/47 (2013.01); A61K 31/519 (2013.01); A61K 31/5375 (2013.01); A61K 31/549 (2013.01); A61K 31/551 (2013.01); A61K 31/635 (2013.01); A61K 45/06 (2013.01);
Abstract
Disclosed are methods of treating fibrosis in a patient in need thereof that includes administering to the patient an amount of an active agent, as identified herein, that is therapeutically effective to inhibit myofibroblast formation and thereby treat the fibrosis. Also disclosed is a recombinant cell line that includes a recombinant gene that expresses a detectable expression product in a dose-dependent response to TGFβ, as well as methods of identifying a compound that inhibits TGFβ-mediated expression of the detectable expression product.